United Therapeutics | UTHR - Selling And Administration Expenses

Stock Price
568.58
Daily Change
-7.21 -1.25%
Monthly
-2.06%
Yearly
86.21%
Q2 Forecast
557.15

United Therapeutics reported $156.6M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Amarin USD 18.97M 1.03M Dec/2025
Ardelyx USD 75.92M 7.69M Dec/2025
Baxter International USD 728M 33M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Esperion Therapeutics USD 39.42M 456K Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Insmed USD 247.26M 34.78M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.03B 719M Mar/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Moderna USD 173M 135M Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026